Abiopharma

🔍 Narayanadas Vivek (Executive)

Company: Oklo Inc. (OKLO)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Acquired 4,806 shares of Class A Common Stock (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,086.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,264 shares of Class A Common Stock at $39.77 per share (Direct)
  Date: 2026-08-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,822.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-08-21 | Code: H | nature_of_ownership: Joint account with spouse | shares_owned_after: 5,000.00
• Sold 4,806 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 13,449.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• F2: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of the RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F3: On February 3, 2025, the Reporting Person was granted 36,508 RSUs, vesting as to 20% of the underlying shares on February 3, 2026 and continuing to vest thereafter in 24 substantially equal monthly installments. On August 21, 2026, 4,806 RSUs vested.